ASH 2022 | Preliminary results examining use of AZD4573 in R/R hematological malignancies
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, outlines results from a Phase I study (NCT03263637) assessing the safety, tolerability, pharmacokinetics, and antitumor activity of the cyclin-dependent kinase-9 (CDK9) inhibitor AZD4573 in patients with relapsed/refractory (R/R) hematological malignancies. Prof. Kater highlights that as a CDK9 inhibitor, AZD4573 decreases the expression of MYC and MCL-1. Overall, this study demonstrated that AZD4573 treatment is associated with mild toxicity and is effective specifically in patients with diffuse large B-cell lymphoma (DLBCL). Prof. Kater concludes by suggesting that future studies will assess the efficacy of acalabrutinib when combined with AZD4573 in patients with DLBCL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Janssen, LAVA: Patents & Royalties: Pending; Astra Zeneca, BMS, Roche/Gennetech, Janssen, Abbvie, LAVA: Membership on an entity’s Board of Directors or advisory committees; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment.
